Mammoth Biosciences stock
Private-market facts for current and former Mammoth Biosciences employees researching their stock.
Overview
Mammoth Biosciences is developing next-generation CRISPR-based gene editing platforms and diagnostics using ultra-small Cas proteins.
Selling Mammoth Biosciences shares
Why shareholders consider selling
Shareholders in Mammoth Biosciences may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Mammoth Biosciences does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Mammoth Biosciences stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Mammoth Biosciences shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Mammoth Biosciences shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round and its reported $1B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Mammoth Biosciences shareholders
Exploring equity in Mammoth Biosciences often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Mammoth Biosciences most recently raised a Series D round in June 2024. The company was valued at $1B. Total funding raised to date is approximately $388M.
Lead investors in this round include Decheng Capital and Foresite Capital.
Founders & company background
Mammoth Biosciences was founded in 2017 by Trevor Martin, Ashley Tehranchi, Janice Chen, Lucas Harrington and is headquartered in Brisbane, CA.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Mammoth Biosciences still a private company?
- Yes, Mammoth Biosciences is currently a private company.
- What is Mammoth Biosciences's latest funding round?
- Mammoth Biosciences's most recent known round is Series D, raised in June 2024.
- What is Mammoth Biosciences's valuation?
- Mammoth Biosciences's latest reported valuation is $1B.
- Who are the investors in Mammoth Biosciences?
- Notable investors include Decheng Capital, Foresite Capital, NFX, Redmile Group, Amazon.
- Can I sell my Mammoth Biosciences stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Mammoth Biosciences stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Mammoth Biosciences data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.